(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 May 2025 (15.05.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/098341 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:
PCT/CN2024/130002

(22) International Filing Date:
05 November 2024 (05.11.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2023/131067
10 November 2023 (10.11.2023) CN

(71) Applicant *(for CN only)*: **INMAGENE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD.** [CN/CN]; 2F Building 9, Hexiang Science And Technology Center, Xiasha Road, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN).

(71) Applicant *(for all designated States except CN)*: **INMAGENE PTE. LTD.** [SG/SG]; 20 EMERALD HILL ROAD, 229302 (SG).

(72) Inventors: **GUO, Chongtian**; Room 487, Zone A, 2nd Floor, 420 Fenglin Road, Xuhui District, Shanghai 200032 (CN). **FAN, Pengcheng**; 2F Building 9, Hexiang Science And Technology Center, Xiasha Road, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN). **LEI, Run**; Room 487, Zone A, 2nd Floor, 420 Fenglin Road, Xuhui District, Shanghai 200032 (CN). **WU, Xiaotong**; Room 487, Zone A, 2nd Floor, 420 Fenglin Road, Xuhui District, Shanghai 200032 (CN). **XU, Steven**; 2F Building 9, Hexiang Science And Technology Center, Xiasha Road, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN).

(74) Agent: **SHANGHAI BESHINING LAW OFFICE**; XUE Qi, WANG Weibin, Room 02, 29th Floor, SFECO Mansion 681 Xiaomuqiao Road, Xuhui District, Shanghai 200032 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/098341 A1

(54) Title: IL-7Ra TARGETING ANTIBODIES AND USES THEREOF

(57) Abstract: Disclosed herein are anti-IL-7Ra antibodies and antigen-binding fragments, polynucleotides encoding the antibodies and antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and antigen-binding fragments. Medical uses of the anti-IL-7Ra antibodies and antigen-binding fragments described herein are also disclosed.